Advanced Search
Article Contents
ABOUT THIS ARTICLE
The Innovation Medicine > 2023 Vol. 1 > No. 1 > 100007
Next Article Previous Article
COMMENTARY   Open Access     Cite

Quizartinib is a good option for AML patients with FLT3-ITD mutations

  • 1.

    Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China

  • 2.

    Department of Hematology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China

  • 3.

    Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing 100044, China

  • 4.

    Research Unit of Key Technique for Diagnosis and Treatments of Hematologic Malignancies, Chinese Academy of Medical Sciences (2019RU029), Beijing 100044, China

  • 5.

    Shanghai Institute of Hematology, National Research Center for Translational Medicine, Shanghai Rui Jin Hospital, Shanghai 200025, China

  • 6.

    Collaborative Innovation Center of Hematology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

  • 7.

    These authors contributed equally

    • Show all affliationsShow less
More Information
The Innovation Medicine  1(1),  https://doi.org/10.59717/j.xinn-med.2023.100007  |  Cite this article
    • FullText(HTML)
  • 加载中
    • REFERENCES
  • [1] Xuan, L., Wang, Y., Huang, F., et al. (2020). Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial. Lancet Oncol. 21: 1201−1212. DOI: 10.1016/S1470-2045(20)30455-1.

    View in Article CrossRef Google Scholar Scopus

    [2] Stone, R.M., Mandrekar, S.J., Sanford, B.L., et al. (2017). Midostaurin plus chemotherapy for acute myeloid Leukemia with a FLT3 mutation. N. Engl. J. Med. 377: 454−464. DOI: 10.1056/NEJMoa1614359.

    View in Article CrossRef Google Scholar

    [3] Erba, H.P., Montesinos, P., Kim, H.J., et al. (2023). Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive Acute Myeloid leukaemia (QuANTUM-First): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 401: 1571−1583. DOI: 10.1016/S0140-6736(23)00464-6.

    View in Article CrossRef Google Scholar

    [4] Dohner, H., Wei, A.H., Appelbaum, F.R., et al. (2022). Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140: 1345−1377. DOI: 10.1182/blood.2022016867.

    View in Article CrossRef Google Scholar Scopus

    [5] Daver, N., Perl, A.E., Maly, J., et al. (2022). Venetoclax plus Gilteritinib for FLT3-mutated relapsed/refractory Acute Myeloid Leukemia. J. Clin. Oncol. 40: 4048−4059.

    View in Article Google Scholar

    • Cited by

  • Cite this article:

    Cao Y., Zhang C., Cao L., et al., (2023). Quizartinib is a good option for AML patients with FLT3-ITD mutations. The Innovation Medicine 1(1), 100007. https://doi.org/10.59717/j.xinn-med.2023.100007
    Cao Y., Zhang C., Cao L., et al., (2023). Quizartinib is a good option for AML patients with FLT3-ITD mutations. The Innovation Medicine 1(1), 100007. https://doi.org/10.59717/j.xinn-med.2023.100007

Welcome!

To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.

PDF
Figures(1)    

Share

  • Share the QR code with wechat scanning code to friends and circle of friends.

Article Metrics

Article views(8091) PDF downloads(1887)

Relative Articles

Cited by

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return

    {{newsColumn.name}}

    {{newsColumn.name}}

    Stay connected

    {{newsColumn.name}}

    Website copyright © Innovation Press. Published articles are licensed under CC BY with copyright retained by the authors.